Nanoliposomal irinotecan plus fluorouracil and folinic acid as a second-line treatment option in patients with metastatic pancreatic ductal adenocarcinoma: a retrospective cohort study

Abstract Background According to the NAPOLI-1 trial, nanoliposomal irinotecan (nal-IRI) plus fluorouracil/folinic acid (5-FU/LV) showed improved overall survival compared to fluorouracil alone for patients with metastatic pancreatic cancer who were previously treated with gemcitabine-based therapy....

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Se Jun Park, Hyunho Kim, Kabsoo Shin, Tae Ho Hong, Ja Hee Suh, Myung Ah Lee
Format: article
Langue:EN
Publié: BMC 2021
Sujets:
Accès en ligne:https://doaj.org/article/4925642ab4544182841d608bafad7bf1
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!